You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196061 - 196070 of 207728 results
  1. TOPIC 277 PHASE II; COMPANION DIAGNOSTICS: PREDICTIVE and PROGNOSTIC TESTS ENABLING

    SBC: Biomarker Strategies, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 277 PHASE II; COMPANION DIAG: PREDICTIVE AND PROGNOSTIC TEST ENABLING PERSO

    SBC: INSIGHT GENETICS, INC.            Topic: NCI

    Not Available

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 305 PHASE II; NOVEL DIGITAL X-RAY SOURCES FOR CANCER IMAGINING APPLICATIONS

    SBC: XINRAY SYSTEMS, INC.            Topic: NCI

    Breast cancer is the most common cancer type among women. Approximately one in every eight women is diagnosed with breast cancer at some time in their life and 30% to 40% of the women who get breast cancer die. Early and accurate detection is viewed asthe best method to decrease breast cancer mortality. Therefore improving the accuracy and effectiveness of breast cancer detection has a vital v ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 296 PHASE II; PLATFORM FOR COLLABORATIVE BIO SIGNAL DATA MANAGEMETN AND ANA

    SBC: ENFORMIA INC.            Topic: NCI

    Platform for Collaborative Bio-signal Data Management and Analysis PUBLIC HEALTH RELEVANCE

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SUVICA INC            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 296 PHASE II; UNIFIED PLATFORM FOR MANAGING OBJECTIVE BEHAVIORAL DATA; HHSN

    SBC: MEI Research, Ltd            Topic: NCI

    Unified Platform for Managing Objective Behavioral Data PUBLIC HEALTH RELEVANCE

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

    SBC: ROCKLAND IMMUNOCHEMICALS, INC.            Topic: NCI

    Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and meso ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE

    SBC: EVORX TECHNOLOGIES, INC.            Topic: NCI

    Targeted molecular imaging of cancer is vital for better personalized medicine, but requires novel imaging agents that recognize key molecular surface cell markers. Her2 is overexpressed in 20-30% of breast cancer and is targeted by Herceptin, yet no molecular imaging agent for Her2 is clinically approved. We propose to use Scanning Unnatural Protease Resistant (SUPR) peptides to develop a novel H ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 324 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER

    SBC: INNOSENSE CORPORATION            Topic: NCI

    This project aims to demonstrate the feasibility of an in vivo diagnostic platform for recognizing indicators of tumor-microenvironment, unambiguously, in biological fluids, tissue phantoms and small animal imaging. Specific project aims are to synthesizeand evaluate cancer-specific, thermoresponsive, nanoparticle-based, near-infrared (NIR) fluorescent contrast agents (ThermoDots) for optical imag ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC 316 PHASE I: OMICS CHIPS FOR CTC ISOLATION AND MOLECULARY ANALYSIS; HHSN261

    SBC: NEWOMICS INC.            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government